A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase Deficiency • Evaluate the safety and tolerability of up to 24 weeks of AG 348 administration in patients with PK deficiency.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune